Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report

EGFR-tyrosine kinase inhibitors (TKIs) have revolutionized the treatment for NSCLC. However, acquired drug resistance often occurs after treatment with EGFR-TKIs. EGFR T790M and C797S mutations are the most common resistance mechanism in patients who failed from first- and third- generation EGFR TKI...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Zhao, Yuanyang, Chen, Yuxing, Huang, Huaying, Li, Xi, Shao, Lin, Ding, Hao
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2021
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8114361/
https://ncbi.nlm.nih.gov/pubmed/33994798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S300556
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller